Tag: design

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

DENVER, June 14, 2025 (GLOBE NEWSWIRE) -- BACXN has recently completed the global assembly and strategic restructuring of its core team, officially launching a comprehensive upgrade covering technology development, security and risk management, and market expansion. This milestone marks the platform transition from a regional startup to global collaborative operations. Supporting this transformation is a core team spanning blockchain, fintech, cybersecurity, and global markets. They not only bring professional expertise but also drive the continuous evolution of BACXN with a systematic vision.

DENVER, June 14, 2025 (GLOBE NEWSWIRE) -- Recently, BACXN has passed compliance regulatory reviews in North America and Southeast Asia, officially launching a cross-jurisdictional risk control and compliance response mechanism. This milestone signifies that the platform not only possesses the qualifications for global operations but has also entered a verifiable and sustainable “deep compliance zone” in its institutional framework. This is not a short-term compliance showcase, but a core part of the long-term trust strategy of BACXN.

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders.

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).